Oxtellar XR Shortage: What Providers and Prescribers Need to Know in 2026

Neurologists, epileptologists, and primary care providers prescribing Oxtellar XR (oxcarbazepine extended-release) are increasingly fielding calls from patients who cannot find their medication at local pharmacies. While Oxtellar XR does not appear on the FDA's official drug shortage list as of 2026, a combination of specialty stocking practices, insurance routing requirements, and prior authorization hurdles creates real-world access challenges that providers need to anticipate and address proactively.

Current Availability Status: FDA Shortage vs. Practical Access

As of 2026, Oxtellar XR is not listed on the FDA MedWatch Drug Shortage database. Supernus Pharmaceuticals continues manufacturing and distributing all three available strengths: 150 mg, 300 mg, and 600 mg extended-release tablets. The challenges patients are encountering are primarily downstream distribution issues — not a failure at the manufacturing level. Specifically:

• Low retail pharmacy stocking: Because Oxtellar XR is a brand-name specialty anticonvulsant with lower dispensing volume relative to common generics, many retail pharmacies do not maintain standing inventory.
• Insurance step therapy and PA requirements: Many commercial and Medicare Part D plans require prior authorization for Oxtellar XR, particularly when generic oxcarbazepine IR or other generics are covered at lower tiers. PA processing delays can leave patients without medication.
• Specialty pharmacy channel restrictions: Some payers route Oxtellar XR through specialty pharmacy networks, meaning standard retail pharmacies may be unable or unwilling to fill the prescription under those plans.

Clinical Rationale: When Is Oxtellar XR Medically Necessary vs. Immediate-Release?

Before addressing access strategies, it's worth reaffirming the clinical cases where Oxtellar XR's once-daily extended-release formulation provides meaningful advantages over twice-daily immediate-release oxcarbazepine (Trileptal):

• Adherence: Once-daily dosing improves compliance in patients who struggle with twice-daily regimens.
• Peak-level tolerability: The extended-release formulation reduces peak plasma MHD concentrations, which correlate with side effects including dizziness and diplopia. Patients who tolerate oxcarbazepine's mechanism but not the IR peak-concentration side effects may benefit from the XR formulation.
• Polypharmacy simplification: Reducing the number of daily doses can be particularly important in pediatric and elderly patients or in those managing multiple medications.

Documentation of these clinical rationales strengthens prior authorization appeals and medical necessity claims.

Managing Prior Authorization for Oxtellar XR

When insurers require prior authorization, document the following to support your PA request:

1. Prior treatment with generic oxcarbazepine IR and documented reason for switching (adherence problems, peak-level side effects).
2. Clinical response and seizure control achieved with Oxtellar XR.
3. Documentation of side effects or adherence failures with alternative formulations.
4. FDA-approved indication: adjunctive therapy for partial-onset seizures in patients 6 years and older (cite the 2024 updated prescribing information).

The Supernus Support program (1-866-398-0833) offers hub services that include benefits investigation and PA support, which can significantly reduce the administrative burden on your practice.

Alternative AEDs If Oxtellar XR Cannot Be Obtained

If a patient genuinely cannot access Oxtellar XR, consider these alternatives for partial-onset seizures:

• Generic oxcarbazepine IR (Trileptal equivalent): Same active ingredient; requires twice-daily dosing and dosage recalibration. Conversion from Oxtellar XR to IR requires dose adjustment — higher doses of Oxtellar XR may have been needed due to differing bioavailability. Monitor for breakthrough seizures during transition.
• Lamotrigine (Lamictal): First-line option; requires slow titration to reduce SJS risk. Not suitable for urgent bridge therapy.
• Levetiracetam (Keppra): Can be initiated at therapeutic doses immediately; widely available generic; few drug interactions; monitor for behavioral adverse effects.
• Lacosamide (Vimpat): Approved as monotherapy and adjunctive therapy for focal seizures; IV formulation available for acute needs.

Critical Safety Reminder: Taper, Do Not Stop

The FDA prescribing information for Oxtellar XR explicitly states that it should be withdrawn gradually to reduce the risk of increased seizure frequency and status epilepticus. Counsel patients who report difficulty filling their prescription to contact the practice immediately rather than stopping on their own. Provide clear after-hours guidance for epilepsy patients approaching medication depletion.

How medfinder Can Help Your Patients

Consider directing patients to medfinder, a service that calls pharmacies on the patient's behalf to identify which locations have Oxtellar XR in stock. Patients provide their medication, dosage, and ZIP code, and results are texted to their phone. This can significantly reduce the time patients spend calling pharmacies when they're running low on a critical seizure medication.